{"preliminary_commentary":{"by_channel":{"x_thread":7},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"EAA232","nct_id":"NCT06948084","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=eaa232-nct06948084. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive daratumumab-hyaluronidase SC over 3-5 minutes on days 1, 8, 15, and 22 of cycles 1 and 2, on days 1 and 15 of cycles 3-6, then on day 1 of subsequent cycles. Patients also receive pomalidomide PO on days 1-21 of each cycle, dexamethasone PO or IV on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo urine and blood sample collection, bone marrow biopsy, and FDG PET/CT throughout the study.","label":"Arm A Treatment I (DPd)","type":"ACTIVE_COMPARATOR"},{"description":"Patients receive daratumumab-hyaluronidase SC over 3-5 minutes on days 1, 8, 15, and 22 of cycles 1 and 2, on days 1 and 15 of cycles 3-6, then on day 1 of subsequent cycles, carfilzomib IV on days 1, 2, 8, 9, 15, and 16 of each cycle, and dexamethasone PO or IV on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo urine and blood sample collection, bone marrow biopsy, and FDG PET/CT throughout the study.","label":"Arm A Treatment II Option 1 (DKd)","type":"ACTIVE_COMPARATOR"},{"description":"Patients receive daratumumab-hyaluronidase SC over 3-5 minutes on days 1, 8, 15, and 22 of cycles 1 and 2, on days 1 and 15 of cycles 3-6 and on day 1 of subsequent cycles, carfilzomib IV on days 1, 8, and 15 of each cycle, and dexamethasone PO or IV on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo urine and blood sample collection, bone marrow biopsy, and FDG PET/CT throughout the study.","label":"Arm A Treatment II Option 2 (DKd)","type":"ACTIVE_COMPARATOR"},{"description":"Patients receive daratumumab-hyaluronidase SC over 3-5 minutes on days 1, 8, 15, and 22 of cycles 1 and 2, on days 1 and 15 of cycles 3-6 and on day 1 of subsequent cycles. Patients also receive teclistamab SC on day 2, 4, 8, 15 and 22 of cycle 1, on days 1, 8, 15, and 22 of cycle 2, on days 1 and 15 of cycles 3-6 and then on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo urine and blood sample collection, bone marrow biopsy, and FDG PET/CT throughout the study.","label":"Arm B (daratumumab, teclistamab)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-02-28","type":"ESTIMATED"},"conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":{"count":80,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Sample Collection","Specimen Collection"],"type":"PROCEDURE"},{"name":"Bone Marrow Biopsy","otherNames":["Biopsy of Bone Marrow","Biopsy, Bone Marrow"],"type":"PROCEDURE"},{"name":"Carfilzomib","otherNames":["Carfilnat","CFZ","Kyprolis","PR 171","PR-171","PR171"],"type":"DRUG"},{"name":"Computed Tomography","otherNames":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","Diagnostic CAT Scan","Diagnostic CAT Scan Service Type","tomography"],"type":"PROCEDURE"},{"name":"Daratumumab and Recombinant Human Hyaluronidase","otherNames":["DARA Co-formulated with rHuPH20","DARA/rHuPH20","Daratumumab + rHuPH20","Daratumumab and Hyaluronidase","Daratumumab and Hyaluronidase-fihj","Daratumumab and vorhyaluronidase","Daratumumab and Vorhyaluronidase Alfa","Daratumumab with rHuPH20","Daratumumab-rHuPH20","Daratumumab/Hyaluronidase-fihj","Daratumumab/rHuPH20 Co-formulation","Darzalex Faspro","Darzalex/rHuPH20","Darzquro","HuMax-CD38-rHuPH20","Recombinant Human Hyaluronidase Mixed with Daratumumab"],"type":"DRUG"},{"name":"Dexamethasone","otherNames":["Aacidexam","Adexone","Aknichthol Dexa","Alba-Dex","Alin","Alin Depot","Alin Oftalmico","Amplidermis","Anemul mono","Auricularum","Auxiloson","Baycadron","Baycuten","Baycuten N","Cortidexason","Cortisumman","Decacort","Decadrol","Decadron","Decadron DP","Decalix","Decameth","Decasone R.p.","Dectancyl","Dekacort","Deltafluorene","Deronil","Desamethasone","Desameton","Dexa-Mamallet","Dexa-Rhinosan","Dexa-Scheroson","Dexa-sine","Dexacortal","Dexacortin","Dexafarma","Dexafluorene","Dexalocal","Dexamecortin","Dexameth","Dexamethasone Intensol","Dexamethasonum","Dexamonozon","Dexapos","Dexinoral","Dexone","Dinormon","Dxevo","Fluorodelta","Fortecortin","Gammacorten","Hemady","Hexadecadrol","Hexadrol","LenaDex","Lokalison-F","Loverine","Methylfluorprednisolone","Millicorten","Mymethasone","Orgadrone","Spersadex","TaperDex","Visumetazone","ZoDex"],"type":"DRUG"},{"name":"FDG-Positron Emission Tomography","otherNames":["FDG","FDG-PET","FDG-PET Imaging"],"type":"PROCEDURE"},{"name":"Pomalidomide","otherNames":["4-Aminothalidomide","Actimid","CC 4047","CC-4047","CC4047","Imnovid","Pomalyst"],"type":"DRUG"},{"name":"Teclistamab","otherNames":["JNJ 64007957","JNJ-64007957","JNJ64007957","Teclistamab-cqyv","Tecvayli"],"type":"DRUG"}],"last_update":"2026-10-28","lead_sponsor":"National Cancer Institute (NCI)","official_title":"A Randomized Phase II Trial for High-Risk Multiple Myeloma That is Refractory or in First Relapse With Daratumumab, Teclistamab (DT) Versus Daratumumab, Pomalidomide, Dexamethasone (DPd) or Daratumumab, Carfilzomib, Dexamethasone (DKd)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-02-28","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Minimal residual disease (MRD) negativity","timeFrame":"After 6 cycles of treatment (cycle length = 28 days), assessed at 6 months"}],"references":[],"start_date":{"date":"2027-05-22","type":"ESTIMATED"},"study_type":"INTERVENTIONAL","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","url":"https://clinicaltrials.gov/study/NCT06948084"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/eaa232-nct06948084"}